Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
NCT ID: NCT00000692
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1\. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3. Pharmacokinetics - how fast SC-48334 reaches the bloodstream, what concentration is reached, and how long it remains in the patient's blood.
SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body, and recent studies have shown that it may also prevent the activity of HIV. The study will attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection in AIDS and advanced ARC by progressively eliminating HIV.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Six patients are enrolled sequentially into each of eight different dose levels and the drug is administered by mouth at least 60 minutes before meals according to the following schedule: Day 1: One-quarter of total assigned daily dose. Patients receive the dosage in the hospital as either an inpatient or outpatient and are observed for 12 hours, during which time they are evaluated and blood is drawn for pharmacokinetic studies. Patients return at 24 and 48 hours for a limited physical examination and additional pharmacokinetic studies. Days 4 - 31: Total assigned daily dose, one-quarter 4 times a day. Patients are observed for at least 5 days in the hospital following the start of this part of the program, during which time clinical, laboratory, and pharmacokinetic information is obtained in order to establish baseline values. After the 6th day, patients are evaluated with a complete physical exam, urinalysis, and laboratory studies once a week and a limited physical exam and brief laboratory studies 3 times a week. At each of the eight dose levels, the second and third patients receive their first dose only after the first patient has been followed for 72 hours after receiving the first dose. Patients 4, 5, and 6 begin treatment only after patients 2 and 3 have completed 14 days of the four-part total dose. Patients are treated on an outpatient basis, with 5 to 6 days spent in the hospital for evaluation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Butyldeoxynojirimycin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Allowed:
* Aerosolized pentamidine.
* Nystatin.
* Clotrimazole.
* Topical acyclovir.
Concurrent Treatment:
Allowed:
* Blood transfusions for = or \> grade 3 hemoglobin toxicity.
Exclusion Criteria
Patients with the following conditions will be excluded:
* Clinical significant diarrhea (\> 3 stools per day for \> 7 days without definable cause).
* Active opportunistic infection, requiring ongoing therapy, at time of enrollment.
* Any malignancy besides Kaposi's sarcoma, basal cell carcinoma, or squamous cell carcinoma unless the squamous cell carcinoma requires ongoing therapy.
* Neurologic disease including dementia, peripheral neuropathy, myelopathy (CDC category IVb).
Concurrent Medication:
Excluded:
* Antimetabolites.
* Alkylating agents.
* Drugs with known hepatic or bone marrow toxicity.
Patients with significant organ dysfunction will be excluded.
Prior Medication:
Excluded:
* Antimetabolites.
* Alkylating agents.
* Excluded within 30 days of study entry:
* Any investigational medication.
* Drugs with anti-HIV activity.
* Excluded within 90 days of study entry:
* Ribavirin treatment.
* Excluded within 6 months of study entry:
* Cancer chemotherapy.
Prior Treatment:
Excluded within 6 months of study entry:
* Radiation therapy.
Patients must demonstrate the following clinical and laboratory findings:
* AIDS or advanced AIDS related complex (ARC), according to Centers for Disease Control (CDC) category IV, excluding neurologic disease in IVb.
* Ability to understand the terms of study participation.
Current use of illicit drugs or abuse of alcohol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
G D Searle
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MS Hirsch
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of California / San Diego Treatment Ctr
San Diego, California, United States
Stanford Univ School of Medicine
Stanford, California, United States
Univ of Miami School of Medicine
Miami, Florida, United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, United States
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts, United States
Julio Arroyo
West Columbia, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tierney M, Pottage J, Kessler H, Fischl M, Richman D, Merigan T, Powderly W, Smith S, Karim A, Sherman J, et al. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):549-53.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACTG 100
Identifier Type: -
Identifier Source: org_study_id